FIA
UTHR icon

FNY Investment Advisers’s United Therapeutics UTHR Stock Holding History

FNY Investment Advisers’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-15
Closed -$3K – 708
2023
Q1 		$3K Buy
+15
New +$3.7K ﹤0.01% 451

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

FNY Investment Advisers's UTHR Position: Q4 2021 in Review

FNY Investment Advisers sold out of United Therapeutics (UTHR) in Q4 2021, closing a stake of 500 shares — an estimated $92K sold.

FNY Investment Advisers first reported a position in UTHR in Q1 2021 and held it in 2 quarters. The position peaked at $92K in Q3 2021. 416 funds tracked by Wall St. Rank hold UTHR as of Q4 2021.

  • FNY Investment Advisers reported no remaining United Therapeutics position as of Q4 2021 after selling out during the quarter.
  • FNY Investment Advisers sold 500 United Therapeutics shares in Q4 2021, an estimated $92K.
  • FNY Investment Advisers first reported a position in United Therapeutics in Q1 2021 and held it in 2 quarters.
  • FNY Investment Advisers's United Therapeutics position peaked at $92K in Q3 2021.
  • 416 funds tracked by Wall St. Rank held United Therapeutics as of Q4 2021.

Based on FNY Investment Advisers's 13F filing for Q4 2021, filed 10 Jan 2022.